TheraRadar
← Back
Data updated: Jul 17, 2026

PROMIUS PHARMA

Specialty
ImmunologyDermatology Execution: Good

PROMIUS PHARMA is a specialty pharmaceutical company focused on Immunology, Dermatology.

1984
Since
3
Drugs
-
Trials
0
New Drugs (2yr)

PROMIUS PHARMA at a Glance

  • Fast trial execution (9 months median completion)

PROMIUS PHARMA's Key Drugs

PROMIUS PHARMA's key approved drugs from the last 15 years (excludes generics, biosimilars and IV formulations).

No active drugs

PROMIUS PHARMA's Recent FDA Approvals

New NDA/BLA approvals for PROMIUS PHARMA over the last two years — novel drugs only, excluding generics and label supplements.

No recent approvals

PROMIUS PHARMA's Therapeutic Areas

PROMIUS PHARMA's approved drugs and pipeline span 2 therapeutic areas, led by Immunology and Dermatology. Weighted by commercial stage — approved drugs count most, then late-stage trials.

Immunology 85%
0 drugs Phase 3: 2 Phase 2: 1 Phase 1: 1
Dermatology 15%
0 drugs Phase 1: 2

PROMIUS PHARMA's Top Competitors

PROMIUS PHARMA's closest competitors by therapeutic-area and drug-target overlap include Pfizer, Eli Lilly, and BAUSCH. Ranked by overlap in therapeutic areas and drug targets across approved drugs and pipeline.

Pfizer big-pharma
Immunology, Dermatology
Eli Lilly big-pharma
Immunology, Dermatology
BAUSCH specialty
Dermatology, Immunology
BAUSCH AND LOMB INC other
Dermatology, Immunology
APOTHECON specialty
Dermatology, Immunology

PROMIUS PHARMA Pipeline Snapshot

PROMIUS PHARMA has 6 active clinical programs from ClinicalTrials.gov — 2 Phase 3, 1 Phase 2 and 3 Phase 1.

2
Phase 3
1
Phase 2
3
Phase 1

Pro Intelligence Preview

Deep insights for investors and analysts

Revenue Insights

  • • Top drug revenue breakdown
  • • Drug-level revenue analysis

Trial Catalysts

  • • Immunology pipeline focus
  • • Phase 3 readout tracking

Patent Risk

  • • Patent expiration timeline
  • • Revenue at risk analysis

Compare Companies

  • • Side-by-side pipeline analysis
  • • Revenue & market share comparison

Execution Intelligence

  • • Phase 3: 2/4 completed
  • • Speed: 9 months avg
Unlock Full Intelligence

Revenue forecasts • Trial milestones • Patent risk modeling

How We Calculate These Metrics

Execution Quality Score

Measures trial completion rates weighted by phase importance. Phase 3 trials count 4x more than Phase 1 because late-stage completion is harder and more valuable.

What counts as "completed": A trial that reached its planned endpoint and reported results. Trials that were terminated early, withdrawn, or suspended are not counted as completed—these often indicate safety issues, lack of efficacy, or strategic pivots.

  • Excellent (80%+): Top-tier execution, most trials reach planned endpoints
  • Good (60-79%): Strong execution with occasional early terminations
  • Fair (40-59%): Average execution, notable rate of terminated/withdrawn trials
  • Needs Improvement (under 40%): High termination rates, execution challenges